News - AMAG Pharmaceuticals, Skyepharma

Filter

Popular Filters

1 to 25 of 29 results

Skyepharma launches Flutiform in France for asthma

10-02-2014

UK drug delivery specialist Skyepharma has received regulatory approval and agreement on pricing reimbursement…

FlutiformFranceMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

Kyorin expects $10 million sales after Flutiform launch in Japan for asthma

19-11-2013

UK drug delivery specialist Skyepharma (LSE: SKP) has announced that Flutiform has been launched in Japan…

Asia-PacificFlutiformKyorin PharmaceuticalsLicensingPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Flutiform trial for COPD initiated in Europe

Flutiform trial for COPD initiated in Europe

19-09-2013

UK drug delivery specialist Skyepharma (LSE: SKP) and privately-held Swiss drugmaker Mundipharma, which…

FlutiformMundipharmaPharmaceuticalResearchRespiratory and PulmonarySkyepharma

Skyepharma's asthma drug helps revenues soar 58% in first half

15-08-2013

UK drug delivery specialist Skyepharma (LSE: SKP) has seen its first half revenues soar 58% to £31.3…

EuropeFinancialFlutiformGSKPharmaceuticalSkyepharma

Flutiform recommended for approval in Japan

01-08-2013

UK drug delivery specialist Skyepharma (LSE SKP) revealed yesterday (July 31) that the Pharmaceutical…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Licensing deals between Xenon and Isis for XEN701, and Access and AMAG for MuGard

10-06-2013

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) revealed that privately-held Canadian firm Xenon Pharmaceuticals…

Access PharmaceuticalsAMAG PharmaceuticalsIsis PharmaceuticalsLicensingMuGardNephrology and HepatologyOncologyPharmaceuticalXEN701Xenon Pharmaceuticals

FDA approves Theravance and GSK's Breo Ellipta to treat COPD

13-05-2013

The US Food and Drug Administration on Friday (May 10) approved Breo Ellipta (fluticasone furoate, an…

BiotechnologyBreo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonarySkyepharmaTheravance Biopharma

SkyePharma partner Kyorin files for Flutiform approval in Japan

26-09-2012

UK drug delivery specialist SkyePharma (LSE: SKP) says that its Japanese development and marketing partner…

Asia-PacificFlutiformKyorin PharmaceuticalsNapp PharmaceuticalsPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma/Mundipharma's Flutiform launched in Germany

23-09-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) last Friday announced the launch of Flutiform,…

EuropeFlutiformMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Flutiform receives UK regulatory approval; solid financials from SkyePharma

24-08-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) yesterday announced that the UK the Medicines…

FinancialFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

European approval for Mundipharma/SkyePharma's asthma drug Flutiform

04-07-2012

After some delays, the European Commission has now adopted a legally binding decision in favor of granting…

EuropeFlutiformMundipharmaPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

SkyePharma partner Kyorin completes Japanese Flutiform clinical program

26-06-2012

UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Two hurdles to jump for SkyePharma, as it changes CEO

31-01-2012

On the same day that UK-based SkyePharma (LSE: SKP) announced that Axel Mueller has resigned as chief…

3MEuropeFinancialFlutiformManagementPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Pacira and SkyePharma leap as FDA approves painkiller Exparel

02-11-2011

New Jersey, USA-based Pacira Pharmaceuticals (Nasdaq: PCRX) and UK drugmaker SkyePharma (LSE: SKP) both…

ExparelFinancialNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalRegulationSkyepharma

Flutiform review to take longer than expected, says SkyePharma

19-10-2011

UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization…

EuropeFlutiformMundi InternationalPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Allos looks to complete merger with AMAG, as third party bows out

11-10-2011

Allos Therapeutics (Nasdaq: ALTH) says that it continues to work with fellow USA-based AMAG Pharmaceuticals…

Allos TherapeuticsAMAG PharmaceuticalsMergers & AcquisitionsPharmaceutical

Exec appointments at SkyePharma, Impax, Ariad and Regeneron

07-09-2011

UK-based drug delivery specialist SkyePharma (LSE: SKP) has appointed Pierre Delavaud as executive vice…

Ariad PharmaceuticalsGenericsImpax LaboratoriesManagementPharmaceuticalRegeneronSkyepharma

SkyePharma seeks funding partner for diabetes product candidate

05-09-2011

Having completed an initial proof-of-concept study for its diabetes care product candidate, SKP-1052,…

DiabetesLicensingPharmaceuticalSkyepharma

1 to 25 of 29 results

Back to top